MX343358B - Tabletas de acetato de ulipristal. - Google Patents

Tabletas de acetato de ulipristal.

Info

Publication number
MX343358B
MX343358B MX2011006106A MX2011006106A MX343358B MX 343358 B MX343358 B MX 343358B MX 2011006106 A MX2011006106 A MX 2011006106A MX 2011006106 A MX2011006106 A MX 2011006106A MX 343358 B MX343358 B MX 343358B
Authority
MX
Mexico
Prior art keywords
amount
ulipristal acetate
acetate tablets
tablets
ulipristal
Prior art date
Application number
MX2011006106A
Other languages
English (en)
Other versions
MX2011006106A (es
Inventor
Gainer Erin
Guillard Hèléne
Gicquel Denis
Henrion Marianne
Gnakamene Céline
Original Assignee
Laboratoire Hra Pharma *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41621124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343358(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire Hra Pharma * filed Critical Laboratoire Hra Pharma *
Publication of MX2011006106A publication Critical patent/MX2011006106A/es
Publication of MX343358B publication Critical patent/MX343358B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una tableta farmacéutica para administración oral que comprende acetato de ulipristal junto con los siguientes excipientes: al menos un diluyente en una cantidad de 50 a 98.5% en peso, al menos un agente enlazante en una cantidad de 0 a 10% en peso, al menos un agente desintegrante en una cantidad de 0.5 a 10% en peso, y al menos un lubricante en una cantidad de 0 a 10% en peso.
MX2011006106A 2008-12-08 2009-12-08 Tabletas de acetato de ulipristal. MX343358B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/329,865 US8512745B2 (en) 2008-12-08 2008-12-08 Ulipristal acetate tablets
PCT/EP2009/066652 WO2010066749A2 (en) 2008-12-08 2009-12-08 Ulipristal acetate tablets

Publications (2)

Publication Number Publication Date
MX2011006106A MX2011006106A (es) 2011-06-24
MX343358B true MX343358B (es) 2016-11-03

Family

ID=41621124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006106A MX343358B (es) 2008-12-08 2009-12-08 Tabletas de acetato de ulipristal.

Country Status (28)

Country Link
US (5) US8512745B2 (es)
EP (2) EP3103445A1 (es)
JP (2) JP5784502B2 (es)
KR (1) KR101733533B1 (es)
CN (2) CN102245173A (es)
AU (1) AU2009326084B2 (es)
BR (1) BRPI0922796A2 (es)
CA (1) CA2745084C (es)
CO (1) CO6400186A2 (es)
CY (1) CY1118099T1 (es)
DK (1) DK2365800T3 (es)
ES (1) ES2596554T3 (es)
HK (1) HK1232134A1 (es)
HR (1) HRP20161262T1 (es)
HU (1) HUE030762T2 (es)
IL (1) IL213247A (es)
LT (1) LT2365800T (es)
MX (1) MX343358B (es)
NZ (1) NZ593498A (es)
PL (1) PL2365800T3 (es)
PT (1) PT2365800T (es)
RS (1) RS55209B1 (es)
RU (1) RU2492853C2 (es)
SI (1) SI2365800T1 (es)
SM (1) SMT201600372B (es)
UA (1) UA101863C2 (es)
WO (1) WO2010066749A2 (es)
ZA (1) ZA201104137B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2615475C3 (de) * 1976-04-09 1984-05-03 Philips Patentverwaltung Gmbh, 2000 Hamburg Sonnenkollektor mit einer Abdeckung aus evakuierten Rohren
JP2682237B2 (ja) 1991-01-28 1997-11-26 日産自動車株式会社 レーザー光出力装置の劣化検出装置
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
EP3106167A1 (en) 2009-04-14 2016-12-21 Laboratoire HRA Pharma Method for on-demand contraception
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
CN102727457B (zh) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 稳定的醋酸优力司特制剂
FR2987271B1 (fr) 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
AU2013265163B2 (en) 2012-05-25 2017-08-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Ulipristal acetate for prevention and treatment of breast tumors
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2999081B1 (fr) * 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
CN103006603B (zh) * 2013-01-11 2015-04-15 山东创新药物研发有限公司 醋酸乌利司他的固体分散体及固体制剂
CN103083326A (zh) * 2013-02-04 2013-05-08 四川尚锐生物医药有限公司 一种醋酸优力司特药物组合物
BR112015025954A2 (pt) * 2013-04-10 2017-07-25 Preglem Sa moduladores do receptor de progesterona para utilização na terapia de fibroides uterinos
CN104865215A (zh) * 2015-05-16 2015-08-26 南京海纳医药科技有限公司 一种醋酸乌利司他片剂及其溶出度测定方法
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
CN107982230A (zh) * 2017-12-25 2018-05-04 郑州泰丰制药有限公司 一种醋酸乌利司他分散片及其制备方法
CN114137115B (zh) * 2021-11-26 2023-08-04 四川尚锐分析检测有限公司 一种采用lc-ms法检测血浆中醋酸优力司特及其代谢物的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5084277A (en) * 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
KR20060130723A (ko) 2004-03-10 2006-12-19 쉐링 악티엔게젤샤프트 분자 분산된 드로스피레논을 포함하는 조성물
DE602006007453D1 (de) 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
US20060246128A1 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compositions containing same
US8475838B2 (en) 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
ES2814343T3 (es) 2006-10-24 2021-03-26 Allergan Pharmaceuticals Int Ltd Composiciones y métodos para suprimir las proliferaciones endometriales
WO2008079245A2 (en) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
KR20090086470A (ko) 2006-12-28 2009-08-12 레프로스 쎄라피우틱스 아이엔씨. 앤티프로게스틴의 개선된 생물학적 이용가능성을 위한 방법들과 제형들
BRPI0806572A2 (pt) 2007-01-17 2014-05-06 Repros Therapeutics Inc Composição e método de produção de efeito antiprogestacional, de indução menstrual, de tratamento de endometriose, da dismenorreia, de tumores dependentes de hormônio endócrino, de meningiomas, de fibriomas uterinos, de inibição da proliferação endometrial uterina, de indução de trabalho de parto e de contracepção.
JP5785392B2 (ja) 2007-04-20 2015-09-30 プレグレム エスアーＰｒｅｇｌｅｍ Ｓ．Ａ． 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター
US20090117183A1 (en) 2007-11-05 2009-05-07 Sabine Fricke Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets

Also Published As

Publication number Publication date
US9844510B2 (en) 2017-12-19
RU2492853C2 (ru) 2013-09-20
US20140228335A1 (en) 2014-08-14
MX2011006106A (es) 2011-06-24
AU2009326084A1 (en) 2011-07-07
AU2009326084B2 (en) 2014-06-05
HK1232134A1 (en) 2018-01-05
RU2011127989A (ru) 2013-01-20
HUE030762T2 (en) 2017-05-29
EP2365800B1 (en) 2016-07-20
CN102245173A (zh) 2011-11-16
CN105267168A (zh) 2016-01-27
CO6400186A2 (es) 2012-03-15
PL2365800T3 (pl) 2017-03-31
SMT201600372B (it) 2017-01-10
CA2745084A1 (en) 2010-06-17
JP2012511041A (ja) 2012-05-17
ES2596554T3 (es) 2017-01-10
WO2010066749A2 (en) 2010-06-17
JP6151727B2 (ja) 2017-06-21
JP2015107994A (ja) 2015-06-11
IL213247A0 (en) 2011-07-31
WO2010066749A3 (en) 2010-08-05
US20120077790A1 (en) 2012-03-29
BRPI0922796A2 (pt) 2017-07-11
HRP20161262T1 (hr) 2016-12-16
US20160287518A1 (en) 2016-10-06
US20180064651A1 (en) 2018-03-08
LT2365800T (lt) 2016-11-10
UA101863C2 (uk) 2013-05-13
US8735380B2 (en) 2014-05-27
KR20110097936A (ko) 2011-08-31
JP5784502B2 (ja) 2015-09-24
CY1118099T1 (el) 2017-06-28
US8512745B2 (en) 2013-08-20
KR101733533B1 (ko) 2017-05-10
PT2365800T (pt) 2016-10-25
CA2745084C (en) 2014-11-18
ZA201104137B (en) 2012-02-29
US20100144692A1 (en) 2010-06-10
NZ593498A (en) 2012-07-27
DK2365800T3 (en) 2016-10-24
EP2365800A2 (en) 2011-09-21
SI2365800T1 (sl) 2017-01-31
RS55209B1 (sr) 2017-01-31
IL213247A (en) 2015-07-30
EP3103445A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
MX343358B (es) Tabletas de acetato de ulipristal.
MX2010008138A (es) Forma de dosis farmaceutica.
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
AU2010308458A8 (en) Orally transformable tablets
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
WO2011104652A3 (en) Veterinary compositions
MX2010007083A (es) Combinacion anti-retroviral.
MX2010003439A (es) Combinacion farmaceutica de aliskiren y valsartan.
MY139913A (en) Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
MX2008010233A (es) Composicion de liberacion modificada, que comprende doxofilina.
BRPI0509014A (pt) comprimidos desintegráveis que compreendem licarbazepina
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
WO2007093168A3 (de) Schnell freisetzende irbesartan-haltige pharmazeutische zusammensetzung
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
TW200833375A (en) Pharmaceutical compositions
MX2011009846A (es) Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration